Skye Bioscience, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $42.4M | $18.7M | $5.8M | $6.0M | $2.9M |
| Operating expenses | $58.2M | $30.2M | $34.7M | $18.3M | $7.8M |
| Operating income | -$58.2M | -$30.2M | -$34.7M | -$18.3M | -$7.8M |
| Interest expense | $0 | $749,308 | $906,270 | $665,133 | $769,159 |
| Pretax income | -$55.9M | -$26.6M | -$37.6M | -$19.5M | -$8.5M |
| Income tax expense | $5,400 | $10,071 | $3,600 | $6,741 | $2,100 |
| Net income | -$55.9M | -$26.6M | -$37.6M | -$19.5M | -$8.5M |
| Balance Sheet | |||||
| Cash and equivalents | $5.9M | $68.4M | $1.3M | — | — |
| Current assets | $27.1M | $70.8M | $11.7M | $8.9M | $9.6M |
| Total assets | $28.3M | $72.8M | $11.9M | $9.1M | $9.9M |
| Current liabilities | $8.2M | $4.3M | $13.9M | $12.1M | $3.9M |
| Total liabilities | $8.3M | $4.6M | $14.1M | $12.1M | $4.0M |
| Stockholders' equity | $20.0M | $68.2M | -$2.1M | -$3.0M | $5.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$43.1M | -$25.2M | -$14.0M | -$12.7M | -$6.5M |
| Depreciation and amortization | $723,352 | $298,640 | $124,251 | $114,998 | $34,131 |
| Stock-based compensation | $7.8M | $8.3M | $987,510 | $629,032 | $869,206 |
| Capital expenditure | $6,312 | $1.6M | $12,550 | $28,060 | $90,866 |
| Free cash flow | -$43.1M | -$26.8M | -$14.0M | -$12.8M | -$6.6M |
Shares outstanding 35.1M · Free float 66.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.